MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Bayer AG

Abierto

SectorFinanzas

21.78 1.92

Resumen

Variación precio

24h

Actual

Mínimo

20.405

Máximo

21.835

Métricas clave

By Trading Economics

Ingresos

3.9B

-328M

Ventas

1.8B

12B

P/B

Media del Sector

30.9

22.015

BPA

1.05

Rentabilidad por dividendo

0.49

Margen de beneficios

-2.796

Empleados

90,587

EBITDA

615M

1.7B

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+20.47% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.49%

3.90%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

422M

22B

Apertura anterior

19.86

Cierre anterior

21.78

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

87 / 542 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Bayer AG Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 mar 2025, 09:37 UTC

Principales Movimientos del Mercado

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 mar 2025, 11:21 UTC

Ganancias

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 mar 2025, 08:45 UTC

Ganancias

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 mar 2025, 07:26 UTC

Ganancias

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mar 2025, 08:38 UTC

Charlas de Mercado

Bayer's Partial Recovery Is in Sight -- Market Talk

5 mar 2025, 13:39 UTC

Charlas de Mercado
Ganancias

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 mar 2025, 13:26 UTC

Charlas de Mercado

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 mar 2025, 08:30 UTC

Charlas de Mercado
Ganancias

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 mar 2025, 06:41 UTC

Ganancias

Bayer Launches Plan to Boost Profitability at Crop Science

5 mar 2025, 06:40 UTC

Ganancias

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 mar 2025, 06:39 UTC

Ganancias

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 mar 2025, 06:39 UTC

Ganancias

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 mar 2025, 06:36 UTC

Ganancias

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 mar 2025, 06:35 UTC

Ganancias

Bayer Guidance is on a Currency Adjusted Basis

5 mar 2025, 06:34 UTC

Ganancias

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 mar 2025, 06:34 UTC

Ganancias

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 mar 2025, 06:33 UTC

Ganancias

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 mar 2025, 06:33 UTC

Ganancias

Bayer Sees 2025 Sales EUR45B-EUR47B

5 mar 2025, 06:32 UTC

Ganancias

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 mar 2025, 06:31 UTC

Ganancias

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 mar 2025, 06:31 UTC

Ganancias

Bayer 4Q Net Loss EUR335M

5 mar 2025, 06:31 UTC

Ganancias

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 mar 2025, 06:31 UTC

Ganancias

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 mar 2025, 06:31 UTC

Ganancias

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 mar 2025, 06:31 UTC

Ganancias

Bayer 4Q Sales EUR11.73B

13 ene 2025, 21:05 UTC

Principales Noticias

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 ene 2025, 15:06 UTC

Adquisiciones, fusiones, absorciones

Bayer Didn't Disclose Financial Details

9 ene 2025, 15:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 ene 2025, 15:05 UTC

Adquisiciones, fusiones, absorciones

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Comparación entre iguales

Cambio de precio

Bayer AG previsión

Precio Objetivo

By TipRanks

20.47% repunte

Estimación a 12 Meses

Media 26.89 EUR  20.47%

Máximo 33 EUR

Mínimo 22 EUR

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bayer AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

10 ratings

1

Comprar

9

Mantener

0

Vender

Puntuación técnica

By Trading Central

21.95 / 22.575Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

87 / 542 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.